LSE: ITRK expands in Latin America—What does Intertek’s Suplilab buy mean for food and medtech testing?

Intertek Group Plc (LSE: ITRK) has announced the acquisition of Costa Rica-based Suplilab, marking a significant expansion of its global ATIC (Assurance, Testing, Inspection and Certification) footprint. The deal gives Intertek immediate access to the fast-growing food safety and medical devices sectors in Central America, a region increasingly shaped by stringent consumer demands and export-oriented industrial growth.

The announcement, made on November 3, 2025, comes as the FTSE 100-listed quality assurance specialist continues to sharpen its regional presence in Latin America. Suplilab, headquartered in San José, is recognized for its advanced capabilities in microbiology, chemistry, and water testing. The Costa Rican firm generated £3.1 million in revenue during 2024 and employs 38 highly skilled professionals across its operations.

This acquisition is seen by analysts as a tactical move that positions Intertek to capitalise on Central America’s surging demand for reliable, science-based quality assurance services, especially in sectors that are not only high-margin but also experiencing strong secular tailwinds from global trade, health regulations, and ESG compliance expectations.

Why is Costa Rica an increasingly strategic hub for food and medical device testing in Latin America?

Costa Rica has steadily become a strategic manufacturing and export base in Latin America, particularly in the medical device and agri-food industries. With consistent GDP growth, a stable regulatory environment, and strong institutional investment in health infrastructure and food processing, the country is now seen as a regional beacon for quality and compliance.

Medical devices now rank among Costa Rica’s top exports, with global players investing in local facilities that require round-the-clock testing, validation, and certification. At the same time, food safety regulations across North America and Europe have placed increased pressure on Central American exporters to ensure compliance with ever-tighter standards.

This convergence of demand for technical excellence and regulatory adherence has created fertile ground for ATIC providers like Suplilab, whose services cover a wide range of microbiological and analytical testing. Intertek’s acquisition allows it to embed itself at the heart of this ecosystem both as a service partner to regional manufacturers and as a compliance enabler for exporters targeting the U.S., EU, and other high-standard markets.

How does Suplilab’s testing expertise fit into Intertek’s global Total Quality Assurance strategy?

Suplilab’s integration strengthens Intertek Group Plc’s science-led value proposition. As a business, Suplilab has focused on high-complexity, high-precision testing protocols, which are core differentiators in the ATIC space. Its work in water testing, chemistry, and microbiology directly supports Intertek’s larger ambition of providing mission-critical quality assurance solutions across supply chains.

By acquiring a local leader rather than entering the market organically, Intertek avoids the slow ramp-up usually associated with regulatory certifications, talent hiring, and client onboarding. Instead, the British multinational gets a running start by accessing Suplilab’s high-margin customer base and plugging them into its global systems, pricing models, and cross-border capabilities.

This model aligns with Intertek’s broader acquisition playbook, which prioritizes technically differentiated assets in growth regions where demand for outsourced testing is rising faster than in mature markets.

What are institutional investors watching following this expansion move in the LATAM region?

As of the market close on November 3, 2025, Intertek Group Plc’s shares (LSE: ITRK) ended at GBX 5,040.00, down 0.49 percent or 25 points for the day. While the dip follows broader FTSE 100 trading sentiment, institutional flows indicate neutral to positive positioning toward Intertek’s emerging market strategy.

The acquisition of Suplilab fits into a pattern of regionally targeted, scale-enhancing deals that have historically helped Intertek defend its premium valuation versus peers. Institutional investors have generally responded well to deals that build upon Intertek’s core specialisation in regulated, high-barrier sectors, especially when they add adjacent revenue and margin upside.

Intertek’s year-to-date stock performance shows moderate volatility, with significant drawdowns in March and July 2025, followed by a strong recovery toward October and early November. Analysts will likely look at this acquisition as a signal of renewed investment momentum rather than a short-term earnings catalyst.

What future growth potential does Intertek see in the Central American ATIC segment?

Intertek’s management has framed the Suplilab acquisition as a springboard into a broader LATAM expansion, specifically within Central America’s ATIC demand curve. Chief Executive Officer André Lacroix noted that the deal opens up high-growth and high-margin opportunities in food and medical device testing, both considered long-term structural themes.

From a macro lens, Latin America’s ATIC services market is expected to grow at 8 to 10 percent CAGR over the next five years, driven by tightening regulations, increased exports, and shifting consumer priorities. Costa Rica’s strong bilateral trade links with the United States, including under CAFTA-DR, also make it an ideal launchpad for testing solutions that meet U.S. FDA and USDA requirements.

Intertek is likely to use Suplilab as a regional anchor from which to launch bundled ATIC offerings, potentially extending into certification, inspection, and digital compliance services. That could also position the British quality assurance group to pitch itself as a partner to regional governments and international development bodies that are investing in food safety, health diagnostics, and supply chain transparency across LATAM.

How does this acquisition align with Intertek’s broader acquisition strategy in emerging markets?

Intertek Group Plc has long favored an asset-light, high-value approach to geographic expansion. Rather than scale via volume-based commoditized testing, it consistently seeks high-margin, capability-rich players that can become innovation hubs. The Suplilab deal aligns with previous acquisitions in Asia, the Middle East, and parts of Africa where Intertek has built scalable clusters around food, pharma, and industrial compliance testing.

With more than 1,000 laboratories and offices across 100 countries, Intertek’s acquisition strategy aims to reduce regional fragmentation while boosting global consistency. Suplilab will now benefit from access to Intertek’s global digital platforms, cross-border client relationships, and operational efficiencies, unlocking a new chapter for both entities.

Key takeaways from Intertek’s acquisition of Suplilab in Costa Rica

• Intertek Group Plc (LSE: ITRK) has acquired Suplilab, a Costa Rica-based food safety and medical device testing provider, for regional expansion in Central America.
• The deal adds £3.1 million in 2024 revenue and 38 skilled personnel to Intertek’s global ATIC network.
• Suplilab specializes in high-margin microbiology, chemistry, and water testing, aligning with Intertek’s science-first assurance strategy.
• The move is seen as a strategic entry into a fast-growing regulatory testing market in Latin America, supported by Costa Rica’s strong medtech and agri-food exports.
• Institutional sentiment remains stable post-announcement, with investors viewing the deal as margin-accretive and regionally significant rather than transformative.